ArticleThe Journal of clinical investigation2001
Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens.
Article in The Journal of clinical investigation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 197 citations in OpenAlex.
- Phosphorylation of inner core heptose is a major determinant of bacterial surface lipopolysaccharide recognition by the innate immune protein hSP-D.The Journal of biological chemistry · 2026Article
- Immune cell and cytokine profiles in a murineJournal of biomedical research · 2026Article
- Surfactant protein D: prognostic insights and emerging therapeutic roles in cancer.Frontiers in immunology · 2026Review
- Enhanced allergic Eustachian tube response in surfactant protein D knockout mice induced by ovalbumin.The World Allergy Organization journal · 2025Article
- Collectins and Ficolins.Advances in experimental medicine and biology · 2025Review
- Interplay of Cytokines and Chemokines in Aspergillosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Revisiting surfactant protein D: an immune surveillance molecule bridging innate and adaptive immunity.Frontiers in immunology · 2024Review
- Humoral Immunity Against Aspergillus fumigatus.Mycopathologia · 2023Review
- Association of serum surfactant protein D and SFTPD gene variants with asthma in Danish children, adolescents, and young adults.Immunity, inflammation and disease · 2022Observational
- Allergic Rhinitis: A Clinical and Pathophysiological Overview.Frontiers in medicine · 2022Review
- In silico study reveals binding potential of rotenone at multiple sites of pulmonary surfactant proteins: A matter of concern.Current research in toxicology · 2021Article
- Soluble pattern recognition molecules: Guardians and regulators of homeostasis at airway mucosal surfaces.European journal of immunology · 2020Review
- Collectins: Innate Immune Pattern Recognition Molecules.Advances in experimental medicine and biology · 2020Review
- Pulmonary Surfactant and Drug Delivery: An Interface-Assisted Carrier to Deliver Surfactant Protein SP-D Into the Airways.Frontiers in bioengineering and biotechnology · 2020Article
- Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells.Frontiers in immunology · 2020Article
- Surfactant Protein D Recognizes Multiple Fungal Ligands: A Key Step to Initiate and Intensify the Anti-fungal Host Defense.Frontiers in cellular and infection microbiology · 2020Review
- Editorial: Odyssey of Surfactant Proteins SP-A and SP-D: Innate Immune Surveillance Molecules.Frontiers in immunology · 2020Article
- Immune regulation by fibroblasts in tissue injury depends on uPARAP-mediated uptake of collectins.The Journal of cell biology · 2019Article
- Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.Frontiers in oncology · 2019Article
- Lipophilic Allergens, Different Modes of Allergen-Lipid Interaction and Their Impact on Asthma and Allergy.Frontiers in immunology · 2019Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic disorder caused by an opportunistic fungal pathogen, Aspergillus fumigatus (AFU:). Lung surfactant proteins SP-A and SP-D can interact with the glycosylated antigens and allergens of AFU:, inhibit specific IgE binding to these allergens, and block histamine release from sensitized basophils. We have now examined the therapeutic effect of exogenous administration of human SP-A, SP-D, and a recombinant fragment of SP-D (rSP-D), in a murine model of pulmonary hypersensitivity induced by AFU: antigens and allergens, which resembles human ABPA immunologically. The ABPA mice exhibited high levels of AFU:-specific IgG and IgE, blood eosinophilia, extensive infiltration of lymphocytes and eosinophils in the lung sections, and a Th2 cytokine response. Treatment with SP-A, SP-D, and rSP-D lowered blood eosinophilia, pulmonary infiltration, and specific Ab levels considerably, which persisted up to 4 days in the SP-A-treated ABPA mice, and up to 16 days in the SP-D- or rSP-D-treated ABPA mice. The levels of IL-2, IL-4, and IL-5 were decreased, while the level of IFN-gamma was raised in the splenic supernatants of the treated mice, indicating a marked shift from Th2 to Th1 response. These results clearly implicate pulmonary SP-A and SP-D in the modulation of allergic reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.